2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma
CABRERA R, FITIAN A, ARARAT M, XU Y, BRUSKO T, WASSERFALL C, ATKINSON M, LIU C, NELSON D. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters 2012, 4: 840-846. PMID: 23205111, PMCID: PMC3506698, DOI: 10.3892/ol.2012.826.Peer-Reviewed Original ResearchSerum levelsEarly hepatocellular carcinomaHepatocellular carcinomaHCC presenceSoluble CD25Pg/Levels of sCD25Healthy control subjectsNovel predictive markerAdvanced cirrhosisPresent study studyAdvanced fibrosisTumor burdenTumor stageControl subjectsHCC patientsPredictive markerImmune factorsGlobal unmet needLarge cohortSCD25PatientsSmall seriesUnmet needSignificant positive correlation
2009
Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25). Digestive Diseases And Sciences 2009, 55: 484-495. PMID: 19714465, PMCID: PMC3161029, DOI: 10.1007/s10620-009-0955-5.Peer-Reviewed Original ResearchConceptsT cell responsesHCC patientsHepatocellular carcinomaCell responsesTumor burdenImpaired T cell responsesLower IFN-γ productionEffector T cell responsesIL-2 receptor alpha chainATP production assaysLevels of sCD25Tolerogenic tumor environmentIFN-γ ELISPOTEffector T cellsT cell immunityT cell reactivityIFN-γ productionIL-2 supplementationT cell defectsDose-dependent mannerReceptor alpha chainIL-2 signalingSerum sCD25Soluble CD25Worse survival